{"id":"sulfur-colloid","_fda":{"id":"22078227-b702-2e8c-e063-6294a90aeb67","set_id":"eeaf70fd-46bd-4fec-ba9d-2366fdf07888","openfda":{"spl_id":["22078227-b702-2e8c-e063-6294a90aeb67"],"brand_name":["Kit for the Prepartion of Technetium Tc99m Sulfur Colloid"],"spl_set_id":["eeaf70fd-46bd-4fec-ba9d-2366fdf07888"],"package_ndc":["45567-0030-1"],"product_ndc":["45567-0030"],"generic_name":["TECHNETIUM TC 99M SULFUR COLLOID"],"product_type":["HUMAN PRESCRIPTION DRUG"],"manufacturer_name":["Sun Pharmaceutical Industries, Inc."],"application_number":["NDA017858"],"is_original_packager":[true]},"version":"14","pregnancy":["8.1 Pregnancy Risk Summary Limited available data with Technetium Tc 99m Sulfur Colloid Injection use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes; technetium Tc 99m crosses the placenta (see Data) . Animal reproduction studies have not been conducted with Technetium Tc 99m Sulfur Colloid Injection. All radiopharmaceuticals, including Technetium Tc 99m Sulfur Colloid Injection, have a potential to cause fetal harm depending on the stage of fetal development and the magnitude of the radiopharmaceutical dose. If considering Technetium Tc 99m Sulfur Colloid Injection administration to a pregnant woman, inform the patient about the potential for adverse pregnancy outcomes based on the radiation dose from the drug and the gestational timing of exposure. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2–4% and 15–20%, respectively. Data Human Data Among 14 infants born to pregnant patients exposed to Technetium Tc 99m Sulfur Colloid Injection for lymph node localization, no birth defects were reported following drug exposure."],"overdosage":["10 OVERDOSAGE The clinical consequences of overdosing with Technetium Tc 99m Sulfur Colloid Injection are not known."],"references":["15 REFERENCES Bergqvist L, Strand S-E, Persson B, et al. Dosimetry in Lymphoscintigraphy of Tc 99m Antimony Sulfide Colloid, J Nucl Med., 23: 698-705, 1982. Summary of Current Radiation Dose Estimates to Humans with Various Liver Conditions from 99m Tc-Sulfur Colloid, MIRD Dose Estimate Report No 3, J Nucl Med., 16: 108A - 108B, 1975 Henrichs et al. Estimation of age-dependent internal dose from radiopharmaceuticals, Phys. Med. Biol., 27: 775-784, 1982. Kocher DC: Radioactive decay data tables. DOE/TIC-11026: 108, 1981."],"description":["11 DESCRIPTION Kit for the Preparation of Technetium Tc 99m Sulfur Colloid Injection contains a multi-dose Reaction Vial, a Solution A vial and a Solution B vial which contain the sterile non-pyrogenic, non-radioactive ingredients necessary to produce Technetium Tc 99m Sulfur Colloid Injection for diagnostic use by subcutaneous, intraperitoneal, or intravenous injection or by oral administration. Each 10 mL multi-dose Reaction Vial contains, in lyophilized form 2 mg sodium thiosulfate anhydrous, 2.3 mg edetate disodium and 18.1 mg bovine gelatin; a Solution A vial contains 1.8 mL of 0.148 N hydrochloric acid solution and a Solution B vial contains 1.8 mL aqueous solution of 24.6 mg/mL sodium biphosphate anhydrous and 7.9 mg/mL sodium hydroxide. When a solution of sterile and non-pyrogenic Sodium Pertechnetate Tc 99m Injection in isotonic saline is mixed with these components, following the instructions provided with the kit, Technetium Tc 99m Sulfur Colloid Injection is formed. The product is intended for subcutaneous, intraperitoneal, or intravenous injection or for oral administration. The precise structure of Technetium Tc 99m Sulfur Colloid Injection is not known at this time. 11.1 Physical Characteristics Technetium Tc 99m decays by isomeric transition with a physical half-life of 6.02 hours. 4 The principal photon that is useful for detection and imaging studies is listed in Table 7. Table 7. Principal Radiation Emission Data 4 Radiation Mean Percent Per Disintegration Mean Energy (keV) Gamma-2 89.07 140.5 4 Kocher DC: Radioactive decay data tables. DOE/TIC-11026: 108, 1981 11.2 External Radiation The specific gamma ray constant for Tc 99m is 0.78 R/millicurie-hr at 1cm. The first half-value layer is 0.017 cm of lead (Pb). A range of values for the relative attenuation of the radiation emitted by this radionuclide that results from interposition of various thicknesses of Pb is shown in Table 8. For example, the use of a 0.25 cm thickness of Pb will attenuate the radiation emitted by a factor of about 1,000. Table 8. Radiation Attenuation by Lead Shielding Shield Thickness (Pb) cm Coefficient of Attenuation 0.017 0.5 0.08 10 -1 0.16 10 -2 0.25 10 -3 0.33 10 -4 To correct for physical decay of this radionuclide, the fractions that remain at selected intervals after the time of calibration are shown in Table 9. Table 9. Physical Decay Chart: Tc 99m, half-life 6.02 hours Hours Fraction Remaining Hours Fraction Remaining 0* 1.000 6 0.501 1 0.891 7 0.447 2 0.794 8 0.398 3 0.708 9 0.355 4 0.631 10 0.316 5 0.562 11 0.282 - - 12 0.251 *Calibration time"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING Kit for the Preparation of Technetium Tc 99m Sulfur Colloid Injection is supplied in a package that contains 5 kits. All kit components are sterile and non-pyrogenic. Each 10mL multi-dose Reaction Vial contains, in lyophilized form, 2 mg sodium thiosulfate anhydrous, 2.3 mg edetate disodium and 18.1 mg bovine gelatin; each Solution A vial contains 1.8 mL 0.148 N hydrochloric acid solution and each Solution B vial contains 1.8 mL aqueous solution of 24.6 mg/mL sodium biphosphate anhydrous and 7.9 mg/mL sodium hydroxide. Included in each 5-kit package are one package insert and 10 radiation labels. Store the kit at 20-25°C (68-77°F) as packaged and after reconstitution. This reagent kit for preparation of a radiopharmaceutical is approved for use by persons licensed pursuant to Section 120.547, Code of Massachusetts Regulation 105, or under equivalent license to the U.S. Nuclear Regulatory Commission or an Agreement State. NDC #45567-0030-1"],"geriatric_use":["8.5 Geriatric Use Clinical studies of Kit for the Preparation of Technetium Tc 99m Sulfur Colloid Injection did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects."],"pediatric_use":["8.4 Pediatric Use The safety and efficacy of Technetium Tc 99m Sulfur Colloid kit in pediatric patients has been shown for the following indications: liver, spleen, and bone marrow imaging, and gastroesophageal and pulmonary aspiration studies."],"effective_time":"20240913","clinical_studies":["14 CLINICAL STUDIES 14.1 Tracer Localization to Lymph Nodes in Breast Cancer A systematic review of 43 publications examined procedures that used the injection of Technetium Tc 99m Sulfur Colloid Injection and a blue dye (tracers) to assist surgeons in the localization of lymph nodes among patients with a primary breast cancer lesion. From these publications, 15 studies were identified for inclusion within a meta-analysis, based upon the following criteria: prospective design, minimum number of 50 lymph node localization procedures, and paired outcome data available for both Technetium Tc 99m Sulfur Colloid Injection and blue dye. Within these studies, the number of procedures ranged from 62 to 6,197; in general one procedure involved a single patient but in some uncommon situations, one patient underwent more than one procedure. The patients received subcutaneous Technetium Tc 99m Sulfur Colloid Injection doses ranging between 0.1 and 2 mCi. The mean age of patients ranged from 52 to 60 years, and almost all were female. Lymph nodes that contained radioactivity were generally localized based upon increased counts, in comparison to a background threshold (e.g., nodes containing a minimum of radioactive counts 3 times higher than background or containing at least 10 fold higher counts than contiguous nodes). Radioactivity was measured using a handheld gamma counter. Table 10 shows the tracer localization rates where the tracer localization rate (%) is defined as the percentage of procedures which had at least one lymph node containing the specific tracer. Random effect meta-analytic measures were used for estimating various rates of tracer localization by procedure along with the respective confidence intervals. The random effect meta-analytical methods take into account the sample size of each study as well as within and between study variability. In general, most procedures involved the resection of lymph nodes in which a tracer had localized to at least one node. However, in some procedures (estimated at approximately 3.4%) neither tracer was localized to a resected lymph node. The reports were insufficient to establish the basis for failed tracer localization. [ see Dosage and Administration (2.4) ] Table 10 . Tracer Localization by Procedure – Breast Cancer* Number of Clinical Studies Number of Procedures BD Present (%) SCI Present (%) Only BD Present (%) Only SCI Present (%) Neither SCI nor BD Present (%) 15 9,213 85.1 94.1 3.8 12.1 3.4 95% Confidence Intervals** 81.4, 88.2 91.4, 96.0 2.8, 5.2 9.9, 15.0 2.1, 5.4 BD = blue dye, SCI = Technetium Tc 99m Sulfur Colloid Injection * Percentage of procedures in which at least one lymph node contained the specific tracer; the percents do not add to 100% due to rounding. ** 95% Confidence Intervals are based on meta-analysis and represent the spread in the individual estimates. In some of the publications, different methods of Technetium Tc 99m Sulfur Colloid Injection administration were compared: intradermal (ID), subareolar (SA) and intraparenchymal (IP) methods. Generally, more favorable results were seen using the ID and SA routes, with less favorable results reported when surgeons used the IP method. 14.2 Tracer Localization to Lymph Nodes in Malignant Melanoma A systematic review of eight publications examined the use of Technetium Tc 99m Sulfur Colloid and a blue dye (tracers) to assist surgeons in the localization of lymph nodes among patients with malignant melanoma. A meta-analysis was performed using data from the studies that reported the resected lymph node content of Technetium Tc 99m Sulfur Colloid Injection and blue dye. Four of the eight publications met this criterion and were included in the meta-analysis. Within these four studies, the number of reported patients ranged from 12 to 94. The patients received subcutaneous Technetium Tc 99m Sulfur Colloid Injection doses ranging between 0.25 to 2 mCi. The patients were aged 15 to 89 years and most (53 to 70%) were male. Lymph nodes that contained radioactivity were generally localized based upon increased counts, in comparison to a background threshold (e.g., nodes containing a minimum of radioactive counts 3 times higher than background). Radioactivity was measured using a handheld gamma counter. Table 11 shows the tracer localization rates where the tracer localization rate (%) is defined as the percentage of patients who had at least one lymph node containing the specific tracer. Random effect meta-analytic measures were used for estimating the various rates of tracer localization by patient along with the respective confidence intervals. The random effect meta-analytical methods take into account the sample size of each study as well as within and between study variability. In general, most patients had resected lymph nodes that contained at least one of the tracers. However, in some patients (estimated at approximately 1.6%) neither tracer was localized to a resected lymph node. The reports were insufficient to establish the basis for failed tracer localization . [ see Dosage and Administration (2.4)]. Table 11 . Tracer Localization by Patient – Malignant Melanoma* Number of Clinical Studies Number of Patients BD Present (%) SCI Present (%) Only BD Present (%) Only SCI Present (%) Neither SCI nor BD Present (%) 4 249 83.6 96.4 3.2 15.5 1.6 95% Confidence Intervals** 73.4, 90.4 92.0, 98.5 1.4, 6.9 9.6, 24.1 0.4, 6.5 BD = blue dye, SCI = Technetium Tc 99m Sulfur Colloid Injection * Percentage of patients in which at least one lymph node contained the specific tracer; the percents do not add to 100% due to rounding. ** 95% Confidence Intervals are based on meta-analysis and represent the spread in the individual estimates."],"pharmacokinetics":["12.3 Pharmacokinetics Following intravenous administration, Technetium Tc 99m Sulfur Colloid Injection is rapidly cleared from the blood by the reticuloendothelial system with a nominal half-life of approximately 2 1/2 minutes. Uptake of the radioactive colloid by organs of the RES is dependent upon both their relative blood flow rates and the functional capacity of the phagocytic cells. In the average patient 80 to 90% of the injected collodial particles are phagocytized by the Kupffer cells of the liver, 5 to 10% by the spleen and the balance by the bone marrow. Following oral ingestion, Technetium Tc 99m Sulfur Colloid is distributed primarily through the gastrointestinal tract with elimination primarily through the feces."],"adverse_reactions":["6 ADVERSE REACTIONS The most frequently reported adverse reactions, across all categories of use and routes of administration, include rash, allergic reaction, urticaria, anaphylaxis/anaphylactic shock, and hypotension. Less frequently reported adverse reactions are fatal cardiopulmonary arrest, seizures, dyspnea, bronchospasm, abdominal pain, flushing, nausea, vomiting, itching, fever, chills, perspiration, numbness, and dizziness. Local injection site reactions, including burning, blanching, erythema, sclerosis, swelling, eschar, and scarring, have also been reported. The most frequently reported adverse reactions include rash, urticaria, anaphylactic shock, and hypotension. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Sun Pharmaceutical Industries, Inc. at 1-800-221-7554 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch"],"contraindications":["4 CONTRAINDICATIONS None None"],"description_table":["
Table 7. Principal Radiation Emission Data 4
RadiationMean Percent Per DisintegrationMean Energy (keV)
Gamma-289.07140.5
","
Table 8. Radiation Attenuation by Lead Shielding
Shield Thickness (Pb) cmCoefficient of Attenuation
0.0170.5
0.0810 -1
0.1610 -2
0.2510 -3
0.3310 -4
","
Table 9. Physical Decay Chart: Tc 99m, half-life 6.02 hours
HoursFraction RemainingHoursFraction Remaining
0*1.00060.501
10.89170.447
20.79480.398
30.70890.355
40.631100.316
50.562110.282
--120.251
"],"drug_interactions":["7 DRUG INTERACTIONS Specific drug-drug interactions have not been studied."],"mechanism_of_action":["12.1 Mechanism of Action Technetium Tc 99m decays by isomeric transition, emitting a photon that can be detected for imaging purposes. [see Description (11.1)] Following subcutaneous injection, Technetium Tc 99m Sulfur Colloid enters the lymphatic capillaries and is transported with lymph to lymph nodes. However, when there is massive nodal metastatic involvement, the normal transport to lymph nodes is lost because few normal cells remain in the node. [ see Dosage and Administration (2.4) ] Following intraperitoneal injection, Technetium Tc 99m Sulfur Colloid mixes with the peritoneal fluid; rate of clearance from the cavity allows assessment of the patency of the shunt. Clearance varies from insignificant, which may occur with complete shunt blockage, to very rapid clearance with subsequent transfer into the systemic circulation when the shunt is patent. Following intravenous injection, Technetium Tc 99m Sulfur Colloid is taken up by the reticuloendothelial system (RES), allowing RES rich structures to be imaged. With oral administration, Technetium Tc 99m Sulfur Colloid is not absorbed accounting for its function in esophageal transit studies, gastroesophageal reflux scintigraphy, and for the detection of pulmonary aspiration of gastric contents."],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Technetium Tc 99m decays by isomeric transition, emitting a photon that can be detected for imaging purposes. [see Description (11.1)] Following subcutaneous injection, Technetium Tc 99m Sulfur Colloid enters the lymphatic capillaries and is transported with lymph to lymph nodes. However, when there is massive nodal metastatic involvement, the normal transport to lymph nodes is lost because few normal cells remain in the node. [ see Dosage and Administration (2.4) ] Following intraperitoneal injection, Technetium Tc 99m Sulfur Colloid mixes with the peritoneal fluid; rate of clearance from the cavity allows assessment of the patency of the shunt. Clearance varies from insignificant, which may occur with complete shunt blockage, to very rapid clearance with subsequent transfer into the systemic circulation when the shunt is patent. Following intravenous injection, Technetium Tc 99m Sulfur Colloid is taken up by the reticuloendothelial system (RES), allowing RES rich structures to be imaged. With oral administration, Technetium Tc 99m Sulfur Colloid is not absorbed accounting for its function in esophageal transit studies, gastroesophageal reflux scintigraphy, and for the detection of pulmonary aspiration of gastric contents. 12.3 Pharmacokinetics Following intravenous administration, Technetium Tc 99m Sulfur Colloid Injection is rapidly cleared from the blood by the reticuloendothelial system with a nominal half-life of approximately 2 1/2 minutes. Uptake of the radioactive colloid by organs of the RES is dependent upon both their relative blood flow rates and the functional capacity of the phagocytic cells. In the average patient 80 to 90% of the injected collodial particles are phagocytized by the Kupffer cells of the liver, 5 to 10% by the spleen and the balance by the bone marrow. Following oral ingestion, Technetium Tc 99m Sulfur Colloid is distributed primarily through the gastrointestinal tract with elimination primarily through the feces."],"indications_and_usage":["1 INDICATIONS AND USAGE Technetium Tc 99m Sulfur Colloid Injection is indicated: In adults, to assist in the: localization of lymph nodes draining a primary tumor in patients with breast cancer or malignant melanoma when used with a hand-held gamma counter. evaluation of peritoneo-venous (LeVeen) shunt patency. In adults and pediatric patients, for imaging: areas of functioning reticuloendothelial cells in the liver, spleen and bone marrow. studies of esophageal transit and, gastroesophageal reflux, and detection of pulmonary aspiration of gastric contents. Technetium Tc 99m Sulfur Colloid Injection is a radioactive diagnostic agent indicated (1) : In adults, to assist in the: localization of lymph nodes draining a primary tumor in patients with breast cancer or malignant melanoma when used with a hand-held gamma counter. evaluation of peritoneo-venous (LeVeen) shunt patency in adults. In adults and pediatric patients, for: imaging areas of functioning reticuloendothelial cells in the liver, spleen and bone marrow. studies of esophageal transit and gastroesophageal reflux, and detection of pulmonary aspiration of gastric contents."],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS Anaphylactic reactions including rare fatalities have occurred following intravenously administered Technetium Tc 99m Sulfur Colloid. Have resuscitation equipment and personnel immediately available ( 5.1 ). 5.1 Anaphylactic Reactions Anaphylactic reactions with bronchospasm, hypotension, urticaria and rare fatalities have occurred following intravenously administered Technetium Tc 99m Sulfur Colloid Injection. Have emergency resuscitation equipment and personnel immediately available. 5.2 Radiation Risks Radiation-emitting products, including Technetium Tc 99m Sulfur Colloid Injection, may increase the risk for cancer, especially in pediatric patients. Use the smallest dose necessary for imaging and ensure safe handling to protect the patient and health care worker. [see Dosage and Administration (2.3)] . 5.3 Altered Distribution, Accumulation of Tracer in the Lungs Technetium Tc 99m Sulfur Colloid Injection is physically unstable, and the particles will settle with time or with exposure to polyvalent cations. These larger particles are likely to be trapped by the pulmonary capillary bed following intravenous injection and result in non-uniform distribution of radioactivity. Agitate the vial adequately before administration of sulfur colloid to avoid particle aggregation and non-uniform distribution of radioactivity. Discard unused drug after 6 hours from the time of formulation. [see Dosage and Administration (2.2)]"],"clinical_studies_table":["
Table 10 . Tracer Localization by Procedure – Breast Cancer*
Number ofClinical StudiesNumber ofProceduresBD Present(%)SCI Present(%)Only BD Present(%)Only SCI Present(%)NeitherSCI nor BD Present(%)
159,21385.194.13.812.13.4
95% Confidence Intervals**81.4, 88.291.4, 96.02.8, 5.29.9, 15.02.1, 5.4
","
Table 11 . Tracer Localization by Patient – Malignant Melanoma*
Number ofClinical StudiesNumber ofPatientsBD Present(%)SCI Present(%)Only BD Present(%)Only SCI Present(%)NeitherSCI nor BD Present(%)
424983.696.43.215.51.6
95% Confidence Intervals**73.4, 90.492.0, 98.51.4, 6.99.6, 24.10.4, 6.5
"],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Animal studies to evaluate the carcinogenicity, mutagenesis, or reproductive toxicity potentials of Technetium Tc 99m Sulfur Colloid have not been conducted."],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Inform patients they may experience a burning sensation at the injection site. Inform lactating woman to pump and discard breast milk for 24 hours after administration of Technetium Tc 99m Sulfur Colloid Injection and minimize close contact with infants for 6 hours after receiving a Technetium Tc 99m Sulfur Colloid Injection ( 8.2 ). Manufactured By: Sun Pharmaceutical Industries, Inc. 29 Dunham Road Billerica, MA 01821 1-800-221-7554 (for International dial: 1-781-275-7120) PL-000001 Rev 2.0 Mar 2020"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION Technetium Tc 99m Sulfur Colloid Injection emits radiation. Use procedures to minimize radiation exposure. Measure patient dose by a suitable radioactivity calibration system immediately before administration. Minimize Tc99m Sulfur Colloid radiation exposure and measure patient doses immediately before administration. Breast cancer or malignant melanoma setting: by subcutaneous injection, 3.7 to 37 MBq (0.1 to 1 mCi in volumes ranging from 0.1 to 1 mL) ( 2.1 ). Peritoneo-venous (LeVeen) shunt setting in adults: ( 2.1 ) by intraperitoneal injection: 37 to 111 MBq (1 to 3 mCi); by percutaneous transtubal injection: 12 to 37 MBq (0.3 to 1 mCi) in a volume not to exceed 0.5 mL. Imaging areas of functioning reticuloendothelial cells by intravenous injection ( 2.1 ): In adults: Liver/spleen imaging: 37 to 296 MBq (1 to 8 mCi); Bone marrow imaging: 111 to 444 MBq (3 to 12 mCi); In pediatric patients: Liver/spleen imaging in newborns: 7.4 to 18.5 MBq (0.2 to 0.5 mCi); Liver/spleen imaging in children: 0.56 to 2.78 MBq (0.015 to 0.075 mCi) per kg of body weight (BW); Bone marrow imaging: 1.11 to 5.55 MBq (0.03 to 0.15 mCi) per kg of BW. Gastroesophageal and pulmonary aspiration studies by oral route ( 2.1 ): In adults: Gastroesophageal studies: 5.55 to 11.1 MBq (0.15 to 0.30 mCi); Pulmonary aspiration studies: 11.1 to 18.5 MBq (0.30 to 0.50 mCi). In pediatric patients: 3.7 to 11.1 MBq (0.10 to 0.30 mCi). 2.1 Recommended Doses Breast cancer or malignant melanoma setting in adults: 3.7 to 37 MBq (0.1 to 1 mCi) in volumes ranging from 0.1 to 1 mL by subcutaneous injection. Peritoneo-venous (LeVeen) shunt setting in adults: 37 to 111 MBq (1 to 3 mCi) by intraperitoneal injection, or 12 to 37 MBq (0.3 to 1 mCi) in a volume not to exceed 0.5 mL by percutaneous transtubal (efferent limb) injection. Patient repositioning or other measures may be used to help assure uniform mixing of the radiopharmaceutical with peritoneal fluid. Imaging areas of functioning reticuloendothelial cells: In adults: liver/spleen imaging: 37 to 296 MBq (1 to 8 mCi) by intravenous injection; bone marrow imaging: 111 to 444 MBq (3 to 12 mCi) by intravenous injection. In pediatric patients: liver/spleen imaging in children: 0.56 to 2.78 MBq (0.015 to 0.075 mCi) per kg of body weight (BW) by intravenous injection; liver/spleen imaging in newborns: 7.4 to 18.5 MBq (0.20 to 0.50 mCi) by intravenous injection; bone marrow imaging: 1.11 to 5.55 MBq (0.03 to 0.15 mCi) per kg of BW by intravenous injection. Gastroesophageal and pulmonary aspiration imaging studies: In adults: gastroesophageal studies: 5.55 to 11.1 MBq (0.15 to 0.30 mCi) by oral administration; pulmonary aspiration studies: 11.1 to 18.5 MBq (0.30 to 0.50 mCi) by oral administration. In pediatric patients: gastroesophageal and pulmonary aspiration studies: 3.7 to 11.1 MBq (0.10 to 0.30 mCi) by oral or nasogastric tube administration. For oral administration, combine the radiopharmaceutical with a milk feeding. For nasogastric tube administration, administer the radiopharmaceutical into the stomach then instill a normal volume of dextrose or milk feeding. 2.2 Drug Preparation and Administration The contents of the two Solution vials, the Solution A vial containing the appropriate acidic solution and the Solution B vial containing the appropriate buffer solution, are intended only for use in the preparation of the Technetium Tc 99m Sulfur Colloid Injection and are not to be directly administered to the patient. Do not use Sodium Pertechnetate Tc 99m containing oxidants to reconstitute this kit. The contents of the kit are not radioactive. However, after the Sodium Pertechnetate Tc 99m is added, maintain adequate shielding of the final preparation. Wear waterproof gloves during the preparation procedure. Do not use Sodium Pertechnetate Tc 99m containing more than 10 micrograms per mL of aluminum ion because a flocculent precipitate may occur and such a precipitate may localize in the lung. The contents of the kit are sterile and non-pyrogenic. This preparation contains no bacteriostatic preservative. Follow the directions carefully and adhere strictly to aseptic procedures during preparation. Prepare Technetium Tc 99m Sulfur Colloid Injection by the following aseptic procedure: Remove the dark brown plastic cap from the Sulfur Colloid multi-dose Reaction Vial and swab the top of the vial closure with alcohol to sterilize the surface. Complete the radiation label and affix to the vial. Place the vial in an appropriate lead-capped radiation shield labeled and identified. With a sterile shielded syringe, aseptically obtain 1 to 3 mL of a suitable, oxidant-free sterile and non-pyrogenic Sodium Pertechnetate Tc 99m, each milliliter containing a maximum activity of 18,500 MBq (500 mCi). Aseptically add the Sodium Pertechnetate Tc 99m to the vial. Place a lead cover on the vial shield and dissolve the reagent by gentle swirling. Just before use, remove the red cap from the Solution A vial and swab the top of the vial closure with alcohol to sterilize the surface. Using a sterile needle and syringe, aseptically withdraw 1.5 mL Solution A from the vial. Aseptically Inject 1.5mL Solution A into the multi-dose Reaction Vial and swirl again. Transfer the multi-dose Reaction Vial from vial shield and place in a vigorously boiling water bath (water bath should be shielded with 1/8” to 1/4” lead) deep enough to cover the entire liquid contents of the vial. Keep the vial in the water bath for five minutes. Remove the multi-dose Reaction Vial from the water bath and place in the lead shield and allow to cool for three minutes. Swab the vial closure again with an antiseptic. Just before use, remove the blue cap from the Solution B vial and swab the top of the vial closure with alcohol to sterilize the surface. Using a sterile needle and syringe, aseptically withdraw 1.5 mL Solution B from the vial. Aseptically Inject 1.5 mL Solution B into the multi-dose Reaction Vial and swirl again. Record time and date of preparation. Allow the preparation to cool to body temperature before use. Maintain adequate shielding of the radioactive colloid preparation at all times. Where appropriate, dilute the preparation with sterile Sodium Chloride Injection to bring the dosage to within the recommended range. Mix the multi-dose Reaction Vial and aseptically withdraw material with a sterile shielded syringe for use within 6 hours of preparation. For optimum results this time should be minimized. The vial contains no bacteriostatic preservative. Store the reconstituted vial at 20 to 25°C (68 to77°F). Discard vial 6 hours after reconstitution. Carefully agitate the shielded syringe immediately prior to administration of sulfur colloid to avoid particles aggregation and non-uniform distribution of radioactivity. Measure the patient dose by a suitable radioactivity calibration system immediately before administration. Check radiochemical purity before patient administration. Inspect Technetium Tc 99m Sulfur Colloid Injection visually for particulate matter and discoloration before administration, whenever solution and container permit. Do not administer the drug if it contains particulate matter or discoloration; dispose of these unacceptable or unused preparations in a safe manner, in compliance with applicable regulations. 2.3 Radiation Dosimetry Subcutaneous injection to assist in lymph node localization Table 1. Estimated Adult Absorbed Radiation Doses from Subcutaneous Administration of Technetium Tc 99m Sulfur Colloid Injection (mSv/MBq and rem/mCi) 1 Target Organ mSv/MBq rem/mCi Injection Site 9.51 35. 2 Lymph Nodes 0.951 3.52 Liver 0.0028 0.0104 Spleen 0.0017 0.00629 Bone Marrow 0.0019 0.00703 Testes 0.0009 0.0033 Ovaries 0.00018 0.00066 Total Body 0.004 0.0148 1 Bergqvist L, Strand S-E, Persson B, et al. Dosimetry in Lymphoscintigraphy of Tc 99m Antimony Sulfide Colloid, J Nucl Med, 23: 698-705, 1982. Intravenous Injection Adult Radiation Doses Table 2. Estimated Adult Absorbed Radiation Doses from Technetium Tc 99m Sulfur Colloid Injection Administration (mSv/MBq and rem/mCi) 2 Diffuse Parenchymal Disease Target Organ Normal Liver Early to Intermediate Intermediate to Advanced mSv/MBq rem/mCi mSv/MBq rem/mCi mSv/MBq rem/mCi Liver 0.091 0.338 0.058 0.213 0.044 0.163 Spleen 0.058 0.213 0.074 0.275 0.115 0.425 Bone Marrow 0.008 0.028 0.012 0.045 0.021 0.079 Testes 0.0003 0.001 0.0005 0.002 0.0008 0.003 Ovaries 0.0016 0.006 0.0022 0.008 0.0032 0.012 Total Body 0.005 0.019 0.005 0.019 0.005 0.018 2 Modified from Summary of Current Radiation Dose Estimates to Humans with Various Liver Conditions from 99m Tc-Sulfur Colloid, MIRD Dose Estimate Report No 3, J Nucl Med 16: 108A - 108B, 197 Pediatric Radiation Doses Table 3A. Estimated Pediatric Absorbed Radiation Doses from Technetium Tc 99m Sulfur Colloid Injection Administration of 1 MBq and 1 mCi for Liver/Spleen and Bone Marrow Imaging (in mSv/MBq and rem/mCi) 3 Age Body Weight Newborn 3.5 kg 1 year 12.1 kg 5 years 20.3 kg 10 years 33.5 kg 15 years 55 kg Absorbed Dose Target Organ Liver mSv/MBq 0.86 0.38 0.22 0.18 0.13 rem/mCi 3.2 1.4 0.82 0.67 0.49 Spleen mSv/MBq 0.76 0.32 0.18 0.13 0.09 rem/mCi 2.8 1.2 0.65 0.49 0.33 Red Marrow mSv/MBq 0.16 0.05 0.03 0.022 0.01 rem/mCi 0.58 0.18 0.11 0.081 0.036 Ovaries mSv/MBq 0.04 0.02 0.0103 0.0043 0.0022 rem/mCi 0.14 0.064 0.038 0.016 0.008 Testes mSv/MBq 0.011 0.006 0.004 0.004 0.001 rem/mCi 0.04 0.021 0.013 0.014 0.002 Total Body mSv/MBq 0.032 0.026 0.018 0.012 0.006 rem/mCi 0.12 0.096 0.066 0.043 0.022 3 from Age-dependent “S” values of Henrichs et al, Berlin 1982, except for the 1-year old. The 1-year old “S” values were taken from phantom work of the Metabolism and Dosimetry Group at ORNL Table 3B. Estimated Pediatric Maximum Absorbed Radiation Doses from Administration of the Maximum Recommended Dose for Technetium Tc 99m Sulfur Colloid Injection (mSv and rem) 3 Age Body Weight Newborn 3.5 kg 1 year 12.1 kg 5 years 20.3 kg 10 years 33.5 kg 15 years 55 kg Maximum Recommended Dose: a* b* a* b* a* b* a* b* a* b* MBq 18.5 22.2 33.3 67.3 55.5 114.7 92.5 186.1 151.7 307.1 mCi 0.5 0.6 0.9 1.82 1.5 3.1 2.5 5.03 4.1 8.3 Maximum Absorbed Dose from Maximum Recommended Dose Administered (mSv and rem) Target Organ Liver mSv 16 19.2 12.6 25.46 12.3 25.42 16.7 33.6 20.1 40.69 rem 1.6 1.92 1.26 2.55 1.23 2.54 1.67 3.36 2.01 4.07 Spleen mSv 14 16.8 10.8 21.83 9.75 20.15 12.2 24.55 13.5 27.33 rem 1.4 1.68 1.08 2.18 0.98 2.02 1.22 2.45 1.35 2.73 Red Marrow mSv 2.9 3.48 1.62 3.27 1.65 3.41 2.03 4.08 1.48 3 rem 0.29 0.35 0.16 0.33 0.17 0.34 0.2 0.41 0.15 0.3 Ovaries mSv 0.7 0.84 0.58 1.17 0.57 1.18 0.4 0.8 0.34 0.69 rem 0.07 0.084 0.058 0.117 0.057 0.118 0.04 0.08 0.034 0.069 Testes mSv 0.2 0.24 0.19 0.38 0.2 0.41 0.35 0.7 0.09 0.18 rem 0.02 0.024 0.019 0.038 0.02 0.041 0.035 0.07 0.009 0.018 Total Body mSv 0.6 0.72 0.86 1.74 0.99 2.05 1.07 2.15 0.9 1.82 rem 0.06 0.072 0.086 0.174 0.099 0.205 0.107 0.215 0.09 0.182 *a liver/spleen imaging *b bone marrow imaging 3 from Age-dependent “S” values of Henrichs et al., Berlin 1982, except for the 1-year old. The 1-year old “S” values were taken from phantom work of the Metabolism and Dosimetry Group at ORNL Oral Administration Table 4. Adult Radiation Absorbed Dose from Oral Administration of 1mCi of Technetium Tc99m Sulfur Colloid Injection (mSv/MBq and rem/mCi) Target Organ Assumed Residence Time (hr.) mSv/MBq rem/mCi Stomach Wall 1.5 0.038 0.14 Small Intestine 4 0.07 0.26 Upper Large Intestine Wall 13 0.13 0.48 Upper Large Intestine Wall 24 0.089 0.33 Ovaries - 0.026 0.096 Testes - 0.001 0.005 Total Body - 0.005 0.018 Intraperitoneal Injection Table 5. Adult Absorbed Radiation Dose from Intraperitoneal Injection of 3 mCi of Technetium Tc 99m Sulfur Colloid (mSv/MBq and rem/mCi) Target Organ Shunt Open Shunt Closed mSv/MBq rem/mCi mSv/MBq rem/mCi Liver 0.092 0.34 0.015 0.056 Ovaries and Testes 0.0003 to 0.0016 0.0012 to 0.006 0.015 0.056 Organs in the Peritoneal Cavity - - 0.015 0.056 Total Body 0.0049 0.0180 0.005 0.019 Assumptions : Calculations for the absorbed radiation dose are based upon an effective half-time of 3 hours for the open shunt and 6.02 hours for the closed shunt and an even distribution of the radiopharmaceutical in the peritoneal cavity with no biological clearance. Other Exposure Estimates Table 6. Radiation Doses to Hospital Personnel (µSv/MBq and mrem/mCi) Technician Preparation of Drug* Administered Drug Target µSv/MBq mrem/mCi µSv/MBq mrem/mCi Extremity Dose 0.016 0.0575 0.07 0.25 Whole Body Dose 0.0007 0.0025 0.003 0.0125 *Using shielded vial and syringe 2.4 Imaging Considerations Breast cancer or malignant melanoma setting in adults: In clinical studies, patients received injection of Technetium Tc 99m Sulfur Colloid Injection and a concomitant blue dye tracer in order to enhance the ability to detect lymph nodes. Visual inspection was performed to identify the blue-labeled nodes and a hand held gamma counter was used to identify nodes concentrating the radiopharmaceutical. Multiple methods were used to detect the concentrated radioactivity within lymph nodes. For example, investigators used thresholds of background radioactivity to localize nodes containing a minimum of radioactive counts 3 times higher than the background or containing at least 10 fold higher counts than contiguous nodes . In clinical studies of patients with malignant melanoma, preoperative lymphoscintigraphy was usually performed using planar imaging techniques to establish a road map of nodal basins and to facilitate intraoperative identification of lymph nodes. [see Clinical Studies (14)] Technetium Tc 99m Sulfur Colloid Injection and other tracers may not localize all lymph nodes and the tracers may differ in their extent of lymph node localization. The lymph node localization of Technetium Tc 99m Sulfur Colloid Injection is dependent upon the underlying patency and structure of the lymphatic system, the extent of functional reticuloendothelial cells within lymph nodes and the radiopharmaceutical injection technique. Distortion of the underlying lymphatic system architecture and function by prior surgery, radiation or extensive metastatic disease may result in failure of the radiopharmaceutical and other tracers to localize lymph nodes. The use of Technetium Tc 99m Sulfur Colloid Injection is intended to supplement palpation, visual inspection and other procedures important to lymph node localization. [see Clinical Studies (14)] . Peritoneo-venous (LeVeen) shunt setting in adults: Following administration of Technetium Tc 99m Sulfur Colloid Injection into the peritoneal cavity, the radiopharmaceutical mixes with the peritoneal fluid. Clearance from the peritoneal cavity varies from insignificant, which may occur with complete shunt blockage, to very rapid clearance with subsequent transfer into the systemic circulation when the shunt is patent. Following transfer into the systemic circulation, the radiopharmaceutical concentrates within the liver (a target organ). Obtain serial images of both the shunt and liver. An adequate evaluation of the difference between total blockage of the shunt and partial blockage may not be feasible in all cases. Transperitoneal absorption of sulfur colloid into the systemic circulation may occur, but it occurs slowly. Therefore, the most definitive scintigraphic evaluation of shunt patency will generally be obtained if there is visualization of both the shunt itself and the liver and/or spleen within the first three hours post intraperitoneal injection of the radiopharmaceutical. Imaging areas of functioning reticuloendothelial cells in liver, spleen or bone marrow: Altered biodistribution with lung and soft tissue uptake instead of reticuloendothelial system has been reported after intravenous injection. The size and physical-chemical properties of the sulfur colloid particles formed from the components of the kit may determine the biodistribution of the colloid and its uptake by the reticuloendothelial system. Diseases affecting the reticuloendothelial system may also alter the expected uptake pattern. Gastroesophageal and pulmonary aspiration imaging studies: To facilitate the imaging of gastroesophageal reflux consider administering Sulfur Colloid by nasogastric tube."],"spl_product_data_elements":["Kit for the Prepartion of Technetium Tc99m Sulfur Colloid Technetium Tc 99m Sulfur Colloid Kit for the Prepartion of Technetium Tc99m Sulfur Colloid Reaction Vial SODIUM THIOSULFATE ANHYDROUS EDETATE DISODIUM TECHNETIUM TC-99M SULFUR COLLOID TECHNETIUM TC-99M SULFUR COLLOID TECHNETIUM TC-99M SULFUR COLLOID GELATIN, UNSPECIFIED Kit for the Prepartion of Technetium Tc99m Sulfur Colloid Solution A HYDROCHLORIC ACID Kit for the Prepartion of Technetium Tc99m Sulfur Colloid Solution B SODIUM HYDROXIDE SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS Kit for the Preparation of Technetium Tc 99m Sulfur Colloid Injection is supplied in a package that contains 5 kits. All components of a kit are sterile and non-pyrogenic. Each 10mL multi-dose Reaction Vial contains, in lyophilized form, 2 mg sodium thiosulfate anhydrous, 2.3 mg edetate disodium and 18.1 mg bovine gelatin; each Solution A vial contains 1.8 mL 0.148 N hydrochloric acid solution and each Solution B vial contains 1.8 mL aqueous solution of 24.6 mg/mL sodium biphosphate anhydrous and 7.9 mg/mL sodium hydroxide. Included in each 5-kit package are one package insert and 10 radiation labels. The Kit for the Preparation of Technetium Tc 99m Sulfur Colloid Injection is supplied as a package that contains 5 kits. Each kit contains three vials: one 10 mL multi-dose Reaction Vial, a Solution A vial and a Solution B vial. The vials contain the sterile non-pyrogenic, non-radioactive ingredients necessary to produce Technetium Tc 99m Sulfur Colloid Injection ( 3 )."],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS Lactation: Advise a lactating woman to pump and discard breast milk for 24 hours and minimize close contact with infants for 6 hours after receiving a Technetium Tc 99m Sulfur Colloid Injection ( 8.2 ). 8.1 Pregnancy Risk Summary Limited available data with Technetium Tc 99m Sulfur Colloid Injection use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes; technetium Tc 99m crosses the placenta (see Data) . Animal reproduction studies have not been conducted with Technetium Tc 99m Sulfur Colloid Injection. All radiopharmaceuticals, including Technetium Tc 99m Sulfur Colloid Injection, have a potential to cause fetal harm depending on the stage of fetal development and the magnitude of the radiopharmaceutical dose. If considering Technetium Tc 99m Sulfur Colloid Injection administration to a pregnant woman, inform the patient about the potential for adverse pregnancy outcomes based on the radiation dose from the drug and the gestational timing of exposure. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2–4% and 15–20%, respectively. Data Human Data Among 14 infants born to pregnant patients exposed to Technetium Tc 99m Sulfur Colloid Injection for lymph node localization, no birth defects were reported following drug exposure. 8.2 Lactation Risk Summary Technetium Tc 99m is excreted in human milk during lactation. Exposure of Technetium Tc 99m Sulfur Colloid Injection to a breastfed infant can be minimized by temporary discontinuation of breastfeeding [see Clinical Considerations] . The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Technetium Tc 99m Sulfur Colloid Injection and any potential adverse effects on the breastfed child from Technetium Tc 99m Sulfur Colloid Injection or from the underlying maternal condition. Clinical Considerations To decrease radiation exposure to the breastfed infant, advise a lactating woman to pump and discard breast milk for 24 hours after administration of Technetium Tc 99m Sulfur Colloid Injection. Following higher dose procedures [greater than 370 MBq (10 mCi)], patients should minimize close contact with infants for 6 hours after receiving a Technetium Tc 99m Sulfur Colloid Injection. 8.4 Pediatric Use The safety and efficacy of Technetium Tc 99m Sulfur Colloid kit in pediatric patients has been shown for the following indications: liver, spleen, and bone marrow imaging, and gastroesophageal and pulmonary aspiration studies. 8.5 Geriatric Use Clinical studies of Kit for the Preparation of Technetium Tc 99m Sulfur Colloid Injection did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects."],"dosage_and_administration_table":["
Table 1. Estimated Adult Absorbed Radiation Doses from Subcutaneous Administration of Technetium Tc 99m Sulfur Colloid Injection (mSv/MBq and rem/mCi) 1
Target OrganmSv/MBqrem/mCi
Injection Site9.5135. 2
Lymph Nodes0.9513.52
Liver0.00280.0104
Spleen0.00170.00629
Bone Marrow0.00190.00703
Testes0.00090.0033
Ovaries0.000180.00066
Total Body0.0040.0148
","
Table 2. Estimated Adult Absorbed Radiation Doses from Technetium Tc 99m Sulfur Colloid Injection Administration (mSv/MBq and rem/mCi) 2
Diffuse Parenchymal Disease
Target OrganNormal LiverEarly to IntermediateIntermediate to Advanced
mSv/MBqrem/mCimSv/MBqrem/mCimSv/MBqrem/mCi
Liver0.0910.3380.0580.2130.0440.163
Spleen0.0580.2130.0740.2750.1150.425
Bone Marrow0.0080.0280.0120.0450.0210.079
Testes0.00030.0010.00050.0020.00080.003
Ovaries0.00160.0060.00220.0080.00320.012
Total Body0.0050.0190.0050.0190.0050.018
","
Table 3A. Estimated Pediatric Absorbed Radiation Doses from Technetium Tc 99m Sulfur Colloid Injection Administration of 1 MBq and 1 mCi for Liver/Spleen and Bone Marrow Imaging (in mSv/MBq and rem/mCi) 3
AgeBody WeightNewborn3.5 kg1 year12.1 kg5 years20.3 kg10 years33.5 kg15 years55 kg
Absorbed Dose
Target Organ
LivermSv/MBq0.860.380.220.180.13
rem/mCi3.21.40.820.670.49
SpleenmSv/MBq0.760.320.180.130.09
rem/mCi2.81.20.650.490.33
Red MarrowmSv/MBq0.160.050.030.0220.01
rem/mCi0.580.180.110.0810.036
OvariesmSv/MBq0.040.020.01030.00430.0022
rem/mCi0.140.0640.0380.0160.008
TestesmSv/MBq0.0110.0060.0040.0040.001
rem/mCi0.040.0210.0130.0140.002
Total BodymSv/MBq0.0320.0260.0180.0120.006
rem/mCi0.120.0960.0660.0430.022
","
Table 3B. Estimated Pediatric Maximum Absorbed Radiation Doses from Administration of the Maximum Recommended Dose for Technetium Tc 99m Sulfur Colloid Injection (mSv and rem) 3
AgeBody WeightNewborn3.5 kg1 year12.1 kg5 years20.3 kg10 years33.5 kg15 years55 kg
MaximumRecommended Dose:a*b*a*b*a*b*a*b*a*b*
MBq18.522.233.367.355.5114.792.5186.1151.7307.1
mCi0.50.60.91.821.53.12.55.034.18.3
Maximum Absorbed Dose from Maximum Recommended Dose Administered (mSv and rem)
Target Organ
LivermSv1619.212.625.4612.325.4216.733.620.140.69
rem1.61.921.262.551.232.541.673.362.014.07
SpleenmSv1416.810.821.839.7520.1512.224.5513.527.33
rem1.41.681.082.180.982.021.222.451.352.73
Red MarrowmSv2.93.481.623.271.653.412.034.081.483
rem0.290.350.160.330.170.340.20.410.150.3
OvariesmSv0.70.840.581.170.571.180.40.80.340.69
rem0.070.0840.0580.1170.0570.1180.040.080.0340.069
TestesmSv0.20.240.190.380.20.410.350.70.090.18
rem0.020.0240.0190.0380.020.0410.0350.070.0090.018
Total BodymSv0.60.720.861.740.992.051.072.150.91.82
rem0.060.0720.0860.1740.0990.2050.1070.2150.090.182
","
Table 4. Adult Radiation Absorbed Dose from Oral Administration of 1mCi of Technetium Tc99m Sulfur Colloid Injection (mSv/MBq and rem/mCi)
Target OrganAssumed Residence Time (hr.)mSv/MBqrem/mCi
Stomach Wall1.50.0380.14
Small Intestine40.070.26
Upper Large Intestine Wall130.130.48
Upper Large Intestine Wall240.0890.33
Ovaries-0.0260.096
Testes-0.0010.005
Total Body-0.0050.018
","
Table 5. Adult Absorbed Radiation Dose from Intraperitoneal Injection of 3 mCi of Technetium Tc 99m Sulfur Colloid (mSv/MBq and rem/mCi)
Target OrganShunt OpenShunt Closed
mSv/MBqrem/mCimSv/MBqrem/mCi
Liver0.0920.340.0150.056
Ovaries and Testes0.0003 to 0.00160.0012 to 0.0060.0150.056
Organs in the Peritoneal Cavity--0.0150.056
Total Body0.00490.01800.0050.019
","
Table 6. Radiation Doses to Hospital Personnel (µSv/MBq and mrem/mCi)
TechnicianPreparation of Drug*Administered Drug
TargetµSv/MBqmrem/mCiµSv/MBqmrem/mCi
Extremity Dose0.0160.05750.070.25
Whole Body Dose0.00070.00250.0030.0125
"],"package_label_principal_display_panel":["PACKAGE/LABEL PRINCIPAL DISPLAY PANEL - VIAL CONTAINER (PART 1 - 10mL multi-dose Reaction Vial) NDC 045567-0030-1 STERILE DIAGNOSTIC MULTIDOSE NON-PYROGENIC Multi-Dose Reaction Vial for use in the Preparation of Technetium Tc 99m Sulfur Colloid Injection. Each 10 mL reaction vial contains in lyophilized form 2.0 mg sodium thiosulfate anhydrous, 2.3 mg edetate disodium and 18.1 mg bovine gelatin. Usual Dosage: See complete prescribing information. Manufactured by: Sun Pharmaceutical Industries, Inc. Billerica, MA 01821 PL-000004 Rev 0.3 Mar 2020 CONTAINS NO BACTERIOSTATIC PRESERVATIVE FOR USE ONLY AFTER LABELING WITH OCIDANT-FREE TECHENTIUM Tc 99m. Store the kit at 20-25°C (68-77°F) [See USP] as packaged and after reconstitution with Technetium Tc 99m. Use within 6 hours after reconstitution. Rx ONLY PL-000004","PACKAGE/LABEL - PRINCIPAL DISPLAY PANEL - VIAL CONTAINER (PART 2 - 3mL Solution A Vial) NDC 045567-0030-1 A Solution A vial contains 1.8mL sterile, non pyrogenic 0.148 N hydrochloric acid solution. To be used only with the Sulfur Colloid Multi-dose Reaction Vial. Single Use Vial-Discard Unused Portion NOT FOR DIRECT INTRAVENOUS INJECTION. R X ONLY . STORE AT 20-25°C (68-77°F) [See USP] Manufactured By: Sun Pharmaceutical Industries, Inc. Billerica, MA 01821 PL-000002 Rev 0.2 Mar 2020 VIAL CONTAINER (PART 2- 3 mL Solution A Vial)","PACKAGE/LABEL - PRINCIPAL DISPALY PANEL - VIAL CONTAINER (PART 3 - 3mL Solution B Vial) NDC 045567-0030-1 B Solution B vial contains 1.8mL sterile, non pyrogenic aqueous solution of 24.6 mg/mL sodium biphosphate anhydrous and 7.9 mg/mL sodium hydroxide. To be used only with the Sulfur Colloid Multi-dose Reaction Vial. Single Use Vial-Discard Unused Portion. NOT FOR DIRECT INTRAVENOUS INJECTION. R X ONLY . STORE AT 20-25°C (68-77°F) [See USP] Manufactured By: Sun Pharmaceutical Industries, Inc. Billerica MA 01821 PL-000003 Rev 0.2 Mar 2020 VIAL CONTAINER (PART 3-3 mL Solution B Vial)","PACKAGE/LABEL - PRINCIPAL DISPLAY PANEL - RADIATION LABEL CAUTION RADIOACTIVE MATERIAL STERILE, NON-PYROGENIC, DIAGNOSTIC MULTIDOSE TECHNETIUM Tc 99m SULFUR COLLOID Subcutaneous, Intravenous, Oral, and Intraperitoneal Use Total MBq (mCi)_____Volume_____ Assay_____MBq/mL(mCi/mL) as of _____ The 10 mL vial contents are made with 2 mg sodium thiosulfate anhydrous, 2.3 mg edetate disodium, 18.1 mg bovine gelatin, the added 1.5 mL of 0.148 N hydrochloric acid solution and the added 1.5 mL aqueous solution of 36.9 mg sodium biphosphate anhydrous and 11.9 mg sodium hydroxide. Contains no bacteriostatic preservative. For use only after labeling with oxidant-free Technetium Tc 99m. Store reconstituted vial at 20-25°C (68-77°F) [See USP]. Use within 6 hours after labeling with Technetium Tc 99m. Usual Dosage: See complete prescribing information. (SEE ENCLOSED PACKAGE INSERT) R x only Manufactured by: Sun Pharmaceutical Industries, Inc. Billerica, MA 01821 PL-000005 Rev 0.2 Mar 2020 RADIATION LABEL","PACKAGE/LABEL - PRINCIPAL DISPLAY PANEL - 5 VIAL BOX NDC 045567-0030-1 Kit for the Preparation of Technetium Tc99m Sulfur Colloid Injection CAUTION: Federal (U.S.A.) law prohibits dispensing without prescription Rx only. Manufactured By: Sun Pharmaceutical Industries, Inc. Billerica, MA 01821 For Customer Service call: 1-800-221-7554 Sterile Diagnostic Multidose Non-Pyrogenic CONTENTS: 1 package insert, 10 radiation labels, 5 multi-dose reaction vials, 5 Solution A vials and 5 Solution B vials. Each 10 mL multi-dose reaction vial contains 2 mg sodium thiosulfate anhydrous, 2.3 mg edetate disodium and 18.1 mg bovine gelatin. Each Solution A vial contains 1.8 mL 0.148 N hydrochloric acid. Each solution B vial contains 1.8 mL aqueous solution of 24.6 mg/mL sodium biphosphate anhydrous and 7.9 mg/mL sodium hydroxide. Contains no bacteriostatic preservative. For intravenous use only after labeling with oxidant-free Technetium Tc 99m. Store the kit at 20-25°C (68-77°F) [See USP] as packaged and after reconstitution Use within 6 hours after labeling with Technetium Tc 99m. Usual Dosage: See complete prescribing information. IMPORTANT: Read enclosed Package Insert for full information on preparation, use and indications. PL-000006 Rev 0.3 Mar 2020 5 VIAL BOX"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Animal studies to evaluate the carcinogenicity, mutagenesis, or reproductive toxicity potentials of Technetium Tc 99m Sulfur Colloid have not been conducted."]},"safety":{"boxedWarnings":[],"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL1201529","moleculeType":"Unknown"},"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Sulfur Colloid","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T06:56:26.410533+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T06:57:54.905014+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T06:56:33.314928+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sulfur Colloid","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T06:56:48.556552+00:00"},"indications.approved":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-20T06:57:45.697506+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T06:56:25.280749+00:00"},"mechanism.oneSentence":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"12.1 Mechanism of Action Technetium Tc 99m decays by isomeric transition, emitting a photon that can be detected for imaging purposes. [see Description (11.1)] Following subcutaneous injection, Technetium Tc 99m Sulfur Colloid enters the lymphatic capillaries and is transported with lymph to lymph nodes. However, when there is massive nodal metastatic involvement, the normal transport to lymph nodes is lost because few normal cells remain in the node. [ see Dosage and Administration (2.4) ] Foll","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T06:57:12.050840+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201529/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T06:56:49.393463+00:00"},"safety.commonSideEffects":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"6 ADVERSE REACTIONS The most frequently reported adverse reactions, across all categories of use and routes of administration, include rash, allergic reaction, urticaria, anaphylaxis/anaphylactic shock, and hypotension. Less frequently reported adverse reactions are fatal cardiopulmonary arrest, seizures, dyspnea, bronchospasm, abdominal pain, flushing, nausea, vomiting, itching, fever, chills, perspiration, numbness, and dizziness. Local injection site reactions, including burning, blanching, e","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T06:57:15.738999+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"NDA017858","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T06:56:25.280765+00:00"}},"_dailymed":{"setId":"4c531280-bc5b-1cf2-e063-6394a90a034a","title":"ACNE BUSTER SALICYLIC ACID DRYING SERUM (ZINC OXIDE,NIACINAMIDE,COLLOIDAL SULFUR,AZELAIC ACID,SALICYLIC ACID.) LIQUID [GUANGZHOU SENMAI BIOTECHNOLOGY CO.,LTD.]"},"aiSummary":"Technetium Tc 99m Sulfur Colloid, marketed by the University of California, San Diego, is a radiopharmaceutical used primarily for lymph node localization in breast cancer or melanoma. Its key strength lies in its mechanism of action, which allows it to effectively enter lymphatic capillaries and be taken up by the reticuloendothelial system, enhancing diagnostic accuracy. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition and potential revenue erosion.","mechanism":{"explanation":"When injected subcutaneously, Technetium Tc 99m Sulfur Colloid travels through lymphatic capillaries to lymph nodes, aiding in the detection of nodal metastasis. When injected intraperitoneally, it mixes with peritoneal fluid, and its clearance rate helps assess shunt patency. Intravenous injection allows imaging of reticuloendothelial system-rich structures.","oneSentence":"Technetium Tc 99m Sulfur Colloid is used for imaging by entering lymphatic capillaries, mixing with peritoneal fluid, or being taken up by the reticuloendothelial system.","technicalDetail":"Technetium Tc 99m decays by isomeric transition, emitting a photon detectable for imaging. Subcutaneous injection leads to entry into lymphatic capillaries and transport to lymph nodes. Intraperitoneal injection results in mixing with peritoneal fluid, and clearance rate assesses shunt patency. Intravenous injection leads to uptake by the reticuloendothelial system (RES). Oral administration is not absorbed, making it useful for esophageal transit studies and detecting pulmonary aspiration."},"_scrapedAt":"2026-03-28T00:10:11.409Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":4,"lastValidatedAt":"2026-04-20T06:57:54.905112+00:00","fieldsConflicting":0,"overallConfidence":0.95},"indications":{"approved":[{"id":"sulfur-colloid-lymph-node-localization-in-bre","name":"Lymph node localization in breast cancer or melanoma","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Adults with breast cancer or malignant melanoma","pivotalTrial":null,"restrictions":[],"patientPopulation":"Adults with breast cancer or malignant melanoma","diagnosticRequired":null,"brandNameForIndication":""},{"id":"sulfur-colloid-evaluation-of-leveen-shunt-pat","name":"Evaluation of LeVeen shunt patency","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Adults","pivotalTrial":null,"restrictions":[],"patientPopulation":"Adults","diagnosticRequired":null,"brandNameForIndication":""},{"id":"sulfur-colloid-imaging-reticuloendothelial-ce","name":"Imaging reticuloendothelial cells","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Adults and pediatric patients","pivotalTrial":null,"restrictions":[],"patientPopulation":"Adults and pediatric patients","diagnosticRequired":null,"brandNameForIndication":""},{"id":"sulfur-colloid-esophageal-transit-and-gastroe","name":"Esophageal transit and gastroesophageal reflux studies","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Adults and pediatric patients","pivotalTrial":null,"restrictions":[],"patientPopulation":"Adults and pediatric patients","diagnosticRequired":null,"brandNameForIndication":""}]},"trialDetails":[{"nctId":"NCT06400004","phase":"PHASE3","title":"Lumason® Infusion vs. Bolus Administrations","status":"RECRUITING","sponsor":"Bracco Diagnostics, Inc","startDate":"2024-07-10","conditions":"Heart Diseases","enrollment":106},{"nctId":"NCT03255577","phase":"NA","title":"Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy For Locally Advanced Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2017-08-17","conditions":"Breast Cancer, Locally Advanced Breast Cancer","enrollment":162},{"nctId":"NCT06693752","phase":"PHASE2","title":"CEUS Evaluation of Hydrocephalus in Neonates and Infants","status":"RECRUITING","sponsor":"Children's Hospital of Philadelphia","startDate":"2026-03-31","conditions":"Hydrocephalus in Infants, Hydrocephalus Acquired","enrollment":20},{"nctId":"NCT06052956","phase":"PHASE2","title":"Efficacy of Methylene Blue Photodynamic Therapy for Treatment of Deep Tissue Abscesses","status":"NOT_YET_RECRUITING","sponsor":"University of Rochester","startDate":"2026-07-15","conditions":"Abscess","enrollment":120},{"nctId":"NCT04854005","phase":"","title":"Use of Sentinel Lymph Node Biopsy in Patients With Early-Stage, Palpable Node-Positive HR+/HER2- Breast Cancer Having Upfront Surgery and Adjuvant Radiation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-04-20","conditions":"Breast Cancer","enrollment":78},{"nctId":"NCT07015736","phase":"PHASE4","title":"Effects of Saccharomyces Boulardii CNCM I-745 on Antibiotic-Associated Perturbation in Children Treated for Acute Respiratory Infections (RESTORE Study)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eskisehir Osmangazi University","startDate":"2025-08-01","conditions":"Antibiotic Associated Diarrhea, Acute Otitis Media, ACUTE SINUSITIS","enrollment":100},{"nctId":"NCT03490929","phase":"PHASE4","title":"CEUS for Blunt Abdominal Trauma in Children","status":"RECRUITING","sponsor":"Children's Hospital of Philadelphia","startDate":"2018-06-01","conditions":"Trauma Abdomen","enrollment":146},{"nctId":"NCT07261982","phase":"NA","title":"Analysis of the Efficacy of Pressure Pad vs Pressure Bandage Immobilisation for Snake Bite First Aid in Healthy Volunteers.","status":"RECRUITING","sponsor":"Townsville University Hospital","startDate":"2025-07-18","conditions":"Snake Bites, Snakebite, Snake Envenomation","enrollment":24},{"nctId":"NCT07244887","phase":"PHASE4","title":"Randomized, Triple-Blind, Placebo-Controlled Trial of Topical Dapsone Gel in Patients With Acne Vulgaris","status":"ENROLLING_BY_INVITATION","sponsor":"Oya Helin Dundar","startDate":"2025-06-17","conditions":"Acne Vulgaris","enrollment":100},{"nctId":"NCT05055206","phase":"NA","title":"Study of Lymphatic Drainage Mapping in Oropharyngeal Cancers","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2021-09-13","conditions":"Oropharynx Cancer","enrollment":12},{"nctId":"NCT05186415","phase":"PHASE1, PHASE2","title":"Contrast Enhanced 3D Echocardiographic Quantification of Right Ventricular Volumes in Repaired CHD","status":"COMPLETED","sponsor":"Nemours Children's Clinic","startDate":"2022-08-23","conditions":"Tetralogy of Fallot, Pulmonary Insufficiency","enrollment":25},{"nctId":"NCT00572481","phase":"PHASE2","title":"Axillary Reverse Mapping","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Arkansas","startDate":"2007-05","conditions":"Cancer of the Breast","enrollment":1000},{"nctId":"NCT02881554","phase":"NA","title":"Sulfur Colloid SPECT/CT in Measuring Liver Function in Patients With Primary or Metastatic Liver Cancer Undergoing Radiation Therapy or Surgery","status":"TERMINATED","sponsor":"University of Washington","startDate":"2016-12-21","conditions":"Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma, Stage IV Liver Cancer","enrollment":41},{"nctId":"NCT07179003","phase":"PHASE2","title":"A Phase 2 Study of Methylene Blue Photodynamic Therapy for Treatment of Breast Abscesses","status":"NOT_YET_RECRUITING","sponsor":"University of Rochester","startDate":"2026-04","conditions":"Breast Abscess","enrollment":50},{"nctId":"NCT04901715","phase":"EARLY_PHASE1","title":"Functional Studies of Novel Genes Mutated in Primary Ciliary Dyskinesia II: Genotype to Phenotype","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2021-06-10","conditions":"Primary Ciliary Dyskinesia","enrollment":27},{"nctId":"NCT07121595","phase":"PHASE2","title":"Personalized Neck Radiation Therapy Directed by Sentinel Lymph Node Biopsy for the Treatment of Oral Cavity Squamous Cell Carcinoma, PRECEDENT Trial","status":"RECRUITING","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2025-07-17","conditions":"Oral Cavity Squamous Cell Carcinoma, Stage I Lip and Oral Cavity Cancer AJCC v8, Stage II Lip and Oral Cavity Cancer AJCC v8","enrollment":50},{"nctId":"NCT05859971","phase":"EARLY_PHASE1","title":"ICG and SLN Mapping","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2023-04-13","conditions":"Breast Cancer","enrollment":10},{"nctId":"NCT00832429","phase":"PHASE2","title":"Lymph Node Mapping in Finding Metastatic Disease in Patients With Sebaceous Gland Cancer of the Eyelid","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2009-02-25","conditions":"Eyelid Sebaceous Gland Carcinoma","enrollment":20},{"nctId":"NCT05108090","phase":"NA","title":"Sentinel Lymph Node Biopsy for Cutaneous Squamous Cell Carcinoma of the Head and Neck","status":"RECRUITING","sponsor":"Indiana University","startDate":"2021-10-25","conditions":"Squamous Cell Carcinoma, Nonmelanoma Skin Cancer, Cutaneous Squamous Cell Carcinoma","enrollment":94},{"nctId":"NCT03282981","phase":"PHASE3","title":"Beta Adrenergic Antagonist for the Healing of Chronic DFU","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2018-07-24","conditions":"Chronic Diabetic Foot Ulcers, Diabetic Neuropathic Ulcers, Non Healing Wound","enrollment":48},{"nctId":"NCT05813496","phase":"PHASE4","title":"Phase IV Trial to Evaluate Efficacy of Alpha-Lipoic Acid in Treating Symptomatic Diabetic Polyneuropathy in Egypt","status":"COMPLETED","sponsor":"Eva Pharma","startDate":"2022-10-26","conditions":"Polyneuropathy, Diabetic","enrollment":430},{"nctId":"NCT03332940","phase":"PHASE1","title":"Safety Evaluation of IV Tc 99m Tilmanocept and Comparison of Imaging With Sulfur Colloid in Subjects With and Without NASH","status":"TERMINATED","sponsor":"Navidea Biopharmaceuticals","startDate":"2017-12-06","conditions":"Nonalcoholic Steatohepatitis, NASH - Nonalcoholic Steatohepatitis","enrollment":6},{"nctId":"NCT06278051","phase":"","title":"An Observational Study to Learn More About How Safe Treatment With Rivaroxaban is in Children in Japan With Venous Thromboembolism","status":"COMPLETED","sponsor":"Bayer","startDate":"2024-02-19","conditions":"Venous Thromboembolism","enrollment":320},{"nctId":"NCT06025344","phase":"PHASE1","title":"A Relative Bioavailability Study With a Novel PanCytoVir™ Oral Suspension (100 mg/ml)","status":"COMPLETED","sponsor":"TrippBio, Inc.","startDate":"2024-09-01","conditions":"Relative Bioavailability","enrollment":14},{"nctId":"NCT06603688","phase":"PHASE4","title":"Study on the Efficacy and Safety of Berberine, Minocycline, Esomeprazole, and Colloidal Bismuth Quadruple Therapy in the Initial Treatment of Helicobacter Pylori.","status":"UNKNOWN","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2023-11-20","conditions":"Helicobacter Pylori Infection, Chronic Gastritis","enrollment":548},{"nctId":"NCT00835354","phase":"PHASE1","title":"Cefprozil for Oral Suspension 250 mg/5 mL, Non-fasting","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2004-05","conditions":"Healthy","enrollment":26},{"nctId":"NCT00840099","phase":"PHASE1","title":"600 mg Amoxicillin/42.9 mg Clavulanate Postassium /5 mL Suspension Under Fasting Conditions","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2002-08","conditions":"Healthy","enrollment":48},{"nctId":"NCT00835549","phase":"PHASE1","title":"Cefdinir for Oral Suspension 250 mg/5mL, Non-fasting","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2005-03","conditions":"Healthy","enrollment":32},{"nctId":"NCT00834574","phase":"PHASE1","title":"Cefdinir for Oral Suspension 250 mg/5mL, Fasting","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2005-02","conditions":"Healthy","enrollment":32},{"nctId":"NCT00835614","phase":"PHASE1","title":"Cefprozil for Oral Suspension 250 mg/5 mL, Fasting","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2004-04","conditions":"Healthy","enrollment":26},{"nctId":"NCT02773238","phase":"PHASE2","title":"FLARE RT for Patients With Stage IIB-IIIB Non-small Cell Lung Cancer: Personalizing Radiation Therapy Using PET/CT and SPECT/CT Imaging","status":"COMPLETED","sponsor":"University of Washington","startDate":"2016-05-20","conditions":"Stage IIB Lung Non-Small Cell Carcinoma AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7","enrollment":51},{"nctId":"NCT06484673","phase":"PHASE1","title":"Bioequivalence Study to Compare Bosentan 32 mg Dispersible Tablets Versus Tracleer® 32 mg Tablets","status":"COMPLETED","sponsor":"Humanis Saglık Anonim Sirketi","startDate":"2024-04-21","conditions":"Pulmonary Arterial Hypertension","enrollment":32},{"nctId":"NCT05073172","phase":"NA","title":"StrataXRT for the Prevention and Treatment of Radiation Dermatitis in Breast Cancer or Head and Neck Cancer Patients","status":"WITHDRAWN","sponsor":"OHSU Knight Cancer Institute","startDate":"2024-01-01","conditions":"Breast Carcinoma, Head and Neck Carcinoma, Radiation-Induced Dermatitis","enrollment":""},{"nctId":"NCT02016820","phase":"NA","title":"Effect of Acid Suppression Medication on Pediatric Microbiome","status":"TERMINATED","sponsor":"Columbia University","startDate":"2014-11","conditions":"Clostridium Difficile Infection","enrollment":7},{"nctId":"NCT04709978","phase":"","title":"Community Acquired Pneumonia in Older Adults","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2021-02-24","conditions":"Pneumonia, Aspiration Pneumonia","enrollment":75},{"nctId":"NCT00006099","phase":"PHASE1","title":"Monoclonal Antibody Therapy in Treating Patients Scheduled for Surgery to Remove Ovarian Cancer","status":"TERMINATED","sponsor":"Ludwig Institute for Cancer Research","startDate":"2000-08-02","conditions":"Ovarian Cancer","enrollment":1},{"nctId":"NCT02971891","phase":"PHASE3","title":"A Phase 3 Study to Evaluate the Efficacy and Safety of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common Warts","status":"COMPLETED","sponsor":"Maruho Co., Ltd.","startDate":"2017-01","conditions":"Cutaneous Common Warts","enrollment":484},{"nctId":"NCT02947126","phase":"PHASE1","title":"Multilevel Models of Therapeutic Response in the Lungs","status":"COMPLETED","sponsor":"Tim Corcoran","startDate":"2017-01","conditions":"Cystic Fibrosis","enrollment":56},{"nctId":"NCT02419807","phase":"NA","title":"Comparison of Use of Indocyanine Green and 99mTc-labeled Radiotracer for Axillary Lymphatic Mapping in Patients With Breast Cancer","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"2015-02-17","conditions":"Stage I Breast Cancer, Stage II Breast Cancer","enrollment":102},{"nctId":"NCT05004207","phase":"","title":"Study of Oro-cecal Transit Time in Healthy Subjects Using Scintigraphy and Lactulose Hydrogen Breath Test.","status":"UNKNOWN","sponsor":"Asian Institute of Gastroenterology, India","startDate":"2021-07-01","conditions":"Small Bowel Disease, Motility Disorder, Irritable Bowel Syndrome","enrollment":50},{"nctId":"NCT04982861","phase":"NA","title":"Bioequivalence Study of Cefixime Trihydrate Dry Syrup in Indonesia Healthy Volunteers","status":"COMPLETED","sponsor":"PT Bernofarm","startDate":"2020-06-15","conditions":"Drug Use","enrollment":22},{"nctId":"NCT03930264","phase":"PHASE1","title":"Bioequivalence of Azathioprine Suspension 10 mg/mL (Jayempi) Versus Azathioprine Tablet 50mg (Imurek®)","status":"COMPLETED","sponsor":"Nova Laboratories Limited","startDate":"2019-04-11","conditions":"Therapeutic Equivalency","enrollment":30},{"nctId":"NCT04839653","phase":"NA","title":"Efficacy and Safety of Selective Digestive Decontamination in the ICU With High Rates of Antibiotic-resistant Bacteria","status":"UNKNOWN","sponsor":"MEDSI Clinical Hospital 1, ICU","startDate":"2021-05-01","conditions":"Pneumonia, Ventilator-Associated, Pneumonia, Bloodstream Infection","enrollment":60},{"nctId":"NCT02856802","phase":"PHASE2","title":"An Efficacy and Safety Study of DFN-02 (Sumatriptan Nasal Spray 10 mg)","status":"COMPLETED","sponsor":"Upsher-Smith Laboratories","startDate":"2016-07-11","conditions":"Migraine Headaches","enrollment":107},{"nctId":"NCT00003654","phase":"NA","title":"Diagnostic Study to Identify Sentinel Lymph Nodes in Women With Stage I or Stage II Breast Cancer","status":"TERMINATED","sponsor":"UNICANCER","startDate":"1997-09","conditions":"Breast Cancer","enrollment":200},{"nctId":"NCT04727021","phase":"PHASE1","title":"A Trial to Learn How Much Rivaroxaban Gets Into the Blood When Taken in Different Forms and How Safe They Are in Healthy Men","status":"COMPLETED","sponsor":"Bayer","startDate":"2017-07-04","conditions":"Healthy Volunteers","enrollment":30},{"nctId":"NCT02336737","phase":"NA","title":"SentiMag® Intraoperative Comparison in Breast Cancer","status":"COMPLETED","sponsor":"Endomagnetics Inc","startDate":"2015-01","conditions":"Breast Cancer","enrollment":160},{"nctId":"NCT04588493","phase":"","title":"Secondary Lymphedema Due to Human Adjuvant Disease","status":"COMPLETED","sponsor":"Hospital Angeles del Pedregal","startDate":"2017-03-01","conditions":"Lymphedema, Secondary, Lymphedema of Leg, Granuloma, Foreign-Body","enrollment":5},{"nctId":"NCT04499742","phase":"","title":"Comparative Assessment of Radioisotope Glucose and Breath Test","status":"UNKNOWN","sponsor":"Augusta University","startDate":"2019-01-21","conditions":"Small Intestinal Bacterial Overgrowth","enrollment":25},{"nctId":"NCT02287675","phase":"PHASE4","title":"Sentinel Lymph Node Biopsy Findings in Patients With Breast Cancer","status":"COMPLETED","sponsor":"Kettering Health Network","startDate":"2015-01-19","conditions":"Breast Cancer","enrollment":40},{"nctId":"NCT04414254","phase":"PHASE1","title":"Bioequivalence of Cefprozil Granule in Healthy Chinese Volunteers","status":"COMPLETED","sponsor":"The Affiliated Hospital of Qingdao University","startDate":"2018-09-11","conditions":"Healthy Volunteers","enrollment":60},{"nctId":"NCT04378231","phase":"NA","title":"Higher Versus Standard Dose of Amoxicillin-clavulanate in Pediatric PBB","status":"UNKNOWN","sponsor":"Second Affiliated Hospital of Wenzhou Medical University","startDate":"2020-05","conditions":"Protracted Bacterial Bronchitis","enrollment":100},{"nctId":"NCT04015375","phase":"PHASE3","title":"Study Comparing Test to Aczone 7.5% and Both to a Placebo Control in the Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"Torrent Pharmaceuticals Limited","startDate":"2019-07-11","conditions":"Acne Vulgaris","enrollment":1150},{"nctId":"NCT03049345","phase":"NA","title":"Gastric Cancer Sentinel Lymph Node Mapping","status":"UNKNOWN","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2016-07-01","conditions":"Gastric Cancer, Sentinel Lymph Node, Early Gastric Cancer","enrollment":40},{"nctId":"NCT02065232","phase":"","title":"Sentinel Lymph Node Mapping Post-Injection Site Pain","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2014-03","conditions":"Breast Cancer","enrollment":52},{"nctId":"NCT01773122","phase":"PHASE1","title":"Safety, Tolerability, and Pharmacokinetics of Dapsone in Acne Vulgaris","status":"COMPLETED","sponsor":"Allergan","startDate":"2013-01-21","conditions":"Acne Vulgaris","enrollment":77},{"nctId":"NCT01677338","phase":"PHASE2","title":"Phase 2 Study to Evaluate the Preliminary Performance of the C13-URA Breath Test Kit in Dyspeptic Subjects","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2013-07","conditions":"Dyspeptic Subjects","enrollment":20},{"nctId":"NCT02944461","phase":"PHASE4","title":"Efficacy and Safety of Aczone 7.5% Gel in the Treatment of Truncal Acne Vulgaris","status":"COMPLETED","sponsor":"Derm Research, PLLC","startDate":"2016-10","conditions":"Acne","enrollment":20},{"nctId":"NCT03354312","phase":"PHASE4","title":"Acceptance and Preference of Lidocaine Gel Compared to Injection Anesthesia After Non Surgical Periodontal Treatment","status":"COMPLETED","sponsor":"Chemische Fabrik Kreussler & CO GmbH","startDate":"2017-12-05","conditions":"Periodontitis","enrollment":94},{"nctId":"NCT01887197","phase":"PHASE1","title":"Repeatability and Response Study of Absorptive Clearance Scans","status":"COMPLETED","sponsor":"Tim Corcoran","startDate":"2013-06","conditions":"Cystic Fibrosis","enrollment":24},{"nctId":"NCT00743314","phase":"EARLY_PHASE1","title":"Single-Photon Emission Computed Tomography, Computed Tomography Lymphoscintigraphy, and Intensity-Modulated Radiation Therapy in Treating Patients Who Have Undergone Surgery for Stage I or Stage II Breast Cancer","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2008-09","conditions":"Breast Cancer, Lymphedema","enrollment":30},{"nctId":"NCT03185650","phase":"NA","title":"Evaluation of Regional Lung Deposition of Inhaled Saline Using the tPAD Device","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2017-07-27","conditions":"Lung Diseases","enrollment":12},{"nctId":"NCT03199560","phase":"PHASE4","title":"Tilmanocept vs Sulfur Colloid in Sentinel Lymph Node Biopsy","status":"UNKNOWN","sponsor":"Memorial Health University Medical Center","startDate":"2017-06-22","conditions":"Sentinel Lymph Node Biopsy, Breast Cancer","enrollment":86},{"nctId":"NCT01431989","phase":"PHASE1","title":"Amoxicillin Bioequivalence Study Brazil - Fast","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-05-27","conditions":"Infections, Bacterial","enrollment":28},{"nctId":"NCT01314963","phase":"NA","title":"Efficacy of Gamma Camera Used Intraoperatively for ID of Sentinel Lymph Nodes w/ Lymphoscintigraphy","status":"COMPLETED","sponsor":"Stanford University","startDate":"2008-06","conditions":"Multiple Myeloma, Breast Cancer","enrollment":50},{"nctId":"NCT01668914","phase":"PHASE3","title":"Internal Mammary Sentinel Lymph Node Biopsy in Early Breast Cancer Patients With Clinically Axillary Node -Positive","status":"COMPLETED","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2014-02","conditions":"Breast Cancer","enrollment":126},{"nctId":"NCT01642511","phase":"PHASE2","title":"Internal Mammary Sentinel Lymph Node Biopsy in Early Breast Cancer Patients With Clinically Axillary Node -Negative","status":"COMPLETED","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2012-01","conditions":"Breast Cancer","enrollment":407},{"nctId":"NCT03061045","phase":"PHASE4","title":"Contrast Enhanced Ultrasound Evaluation of Brain Perfusion in Neonatal Post-Hemorrhagic Hydrocephalus","status":"WITHDRAWN","sponsor":"Johns Hopkins University","startDate":"2017-04-01","conditions":"Neonatal Post-Hemorrhagic Hydrocephalus","enrollment":""},{"nctId":"NCT01115244","phase":"PHASE4","title":"Use of Dapsone Gel, 5% for Treating Dermatitis Herpetiformis","status":"TERMINATED","sponsor":"Vanderbilt University Medical Center","startDate":"2010-07","conditions":"Dermatitis Herpetiformis","enrollment":1},{"nctId":"NCT01771666","phase":"PHASE2","title":"Pilot Indocyanine Green Imaging for Mapping of Arm Draining Lymphatics & Nodes in Breast Cancer","status":"COMPLETED","sponsor":"Stanford University","startDate":"2012-07","conditions":"Breast Cancer","enrollment":23},{"nctId":"NCT01660412","phase":"NA","title":"Does Alkalinization Reduce Perceived Pain Levels During Sentinel Lymph Node Imaging?","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"2012-08-01","conditions":"Pain","enrollment":60},{"nctId":"NCT00070317","phase":"NA","title":"Lymph Node Mapping and Sentinel Lymph Node Identification in Patients With Stage IB1 Cervical Cancer","status":"TERMINATED","sponsor":"Gynecologic Oncology Group","startDate":"2004-06","conditions":"Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma","enrollment":102},{"nctId":"NCT01486199","phase":"NA","title":"Imaging Airway Liquid Absorption in Cystic Fibrosis","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2011-10","conditions":"Cystic Fibrosis","enrollment":20},{"nctId":"NCT01684423","phase":"PHASE2","title":"Oral Rivaroxaban in Children With Venous Thrombosis","status":"COMPLETED","sponsor":"Bayer","startDate":"2013-02-19","conditions":"Venous Thrombosis","enrollment":64},{"nctId":"NCT00541190","phase":"NA","title":"Absorptive Clearance in the Cystic Fibrosis Airway","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2007-10","conditions":"Cystic Fibrosis","enrollment":21},{"nctId":"NCT02057393","phase":"NA","title":"Infrared Lymphangiography as a Method of Sentinel Node Identification","status":"COMPLETED","sponsor":"Milton S. Hershey Medical Center","startDate":"2014-06","conditions":"Melanoma, Sentinel Node","enrollment":89},{"nctId":"NCT00964366","phase":"PHASE4","title":"Study to Determine and Compare the Tolerance and Irritation Potential of Topical Acne Medications","status":"COMPLETED","sponsor":"Stiefel, a GSK Company","startDate":"2009-07","conditions":"Acne Vulgaris","enrollment":53},{"nctId":"NCT01898403","phase":"NA","title":"Lymph Node Mapping Using Indocyanine Green Solution in Diagnosing Patients With Malignant Melanoma","status":"COMPLETED","sponsor":"Stanford University","startDate":"2013-06","conditions":"Recurrent Melanoma","enrollment":50},{"nctId":"NCT00883883","phase":"PHASE1","title":"To Demonstrate the Relative Bioequivalence of Cefdinir and Omnicel 250 mg/5 ml Oral Suspension Fed Conditions","status":"COMPLETED","sponsor":"Sandoz","startDate":"2005-04","conditions":"Healthy","enrollment":40},{"nctId":"NCT00881400","phase":"PHASE1","title":"To Demonstrate the Relative Bioavailability of Cefzil 250 mg/5 ml Cefprozil Oral Suspension Fed Conditions","status":"COMPLETED","sponsor":"Sandoz","startDate":"2004-06","conditions":"Healthy","enrollment":24},{"nctId":"NCT00882570","phase":"PHASE1","title":"To Demonstrate the Relative Bioequivalence of Cefdinir and Omnicel 250mg/5 ml Oral Suspension Fasting Conditions","status":"COMPLETED","sponsor":"Sandoz","startDate":"2005-04","conditions":"Healthy","enrollment":40},{"nctId":"NCT00881153","phase":"PHASE1","title":"To Demonstrate the Relative Bioavailability of Cefzil 250 mg/5 ml Cefprozil Oral Suspension Following a 10 ml Dose Fasting Conditions.","status":"COMPLETED","sponsor":"Sandoz","startDate":"2004-05","conditions":"Healthy","enrollment":20},{"nctId":"NCT02145884","phase":"PHASE2","title":"Topical Timolol Gel for the Treatment of Infantile Hemangiomas","status":"COMPLETED","sponsor":"Rady Children's Hospital, San Diego","startDate":"2014-05","conditions":"Hemangioma","enrollment":26},{"nctId":"NCT00450723","phase":"NA","title":"Thoracoscopic Sentinel Lymph Node Biopsy in Patients With Stage I or Stage II Breast Cancer","status":"COMPLETED","sponsor":"University of Miami","startDate":"2004-05","conditions":"Breast Cancer","enrollment":39},{"nctId":"NCT01931150","phase":"PHASE3","title":"Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2013-08","conditions":"Cetuximab-induced Papulopustular (Acneiform) Rash Who Have, Metastatic Colorectal Cancer or Head and Neck Squamous Cell Carcinoma","enrollment":11},{"nctId":"NCT01381315","phase":"PHASE2","title":"Axillary Reverse Mapping","status":"COMPLETED","sponsor":"University of Kansas Medical Center","startDate":"2009-09","conditions":"Breast Cancer","enrollment":210},{"nctId":"NCT01441310","phase":"PHASE2","title":"Laparoscopic Sentinel Node Navigation Surgery for Gastric Cancer","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2010-07","conditions":"Gastric Cancer","enrollment":101},{"nctId":"NCT02865005","phase":"PHASE3","title":"Trial of Dapsone 5.0% Gel in the Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"Seegpharm S.A.","startDate":"2016-02","conditions":"Acne Vulgaris","enrollment":2361},{"nctId":"NCT00042926","phase":"NA","title":"Diagnostic Trial in Patients Who Are Undergoing Surgery for Early Stage Mouth Cancer","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2002-05","conditions":"Head and Neck Cancer","enrollment":161},{"nctId":"NCT00314171","phase":"PHASE3","title":"A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2005-10","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":437},{"nctId":"NCT00314158","phase":"PHASE3","title":"A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2005-11","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":523},{"nctId":"NCT02869152","phase":"NA","title":"Sentinel Lymph Node Mapping in Rectal Cancer","status":"UNKNOWN","sponsor":"University of Virginia","startDate":"2016-08","conditions":"Rectal Neoplasms","enrollment":26},{"nctId":"NCT00575744","phase":"PHASE2","title":"Sentinel Lymph Node Biopsy Using Peritumoral Injection With Blue Dye Confirmation","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"1998-12","conditions":"Breast Cancer","enrollment":699},{"nctId":"NCT02112240","phase":"NA","title":"Feasibility Study to Develop Sentinel Lymph Node Mapping in Rectal Cancer Patients","status":"WITHDRAWN","sponsor":"University of Virginia","startDate":"2013-05","conditions":"Rectal Cancer","enrollment":""},{"nctId":"NCT00012168","phase":"NA","title":"Lymphoscintigraphy to Detect Early Metastases in Patients With Cancer of the Mouth or Throat","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"1999-05","conditions":"Head and Neck Cancer","enrollment":""},{"nctId":"NCT02373735","phase":"NA","title":"Effect of SVV Guided Fluid Therapy on Blood Loss and Postoperative Outcomes","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2015-03","conditions":"Bladder Cancer","enrollment":64},{"nctId":"NCT00717886","phase":"NA","title":"Upper Extremity Lymphatic Mapping for Breast Cancer Patients","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2008-06","conditions":"Breast Cancer, Axillary Lymph Node Dissection","enrollment":13},{"nctId":"NCT02570581","phase":"PHASE1","title":"MELA Study - Hedonic Study on the Taste of Drugs Crushed in Food: Observational Study Involving 16 Healthy Volunteers","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2014-06","conditions":"Healthy","enrollment":16},{"nctId":"NCT02294565","phase":"PHASE1, PHASE2","title":"VST-1001 (Dilute Fluorescein) for Lymphatic Mapping & Localization of Lymph Nodes in Patients With Breast Cancer","status":"UNKNOWN","sponsor":"Vestan, Inc.","startDate":"2014-06","conditions":"Breast Cancer","enrollment":147},{"nctId":"NCT01187108","phase":"PHASE1, PHASE2","title":"Study of Cobalt's Role in Excessive Erythrocytosis Among High Altitude Dwellers in Cerro de Pasco, Peru","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2013-06","conditions":"Erythrocytosis, Mountain Sickness","enrollment":85}],"_emaApprovals":[],"_faersSignals":[{"count":12,"reaction":"RADIOISOTOPE SCAN ABNORMAL"},{"count":10,"reaction":"DRUG INEFFECTIVE"},{"count":8,"reaction":"URTICARIA"},{"count":7,"reaction":"NAUSEA"},{"count":7,"reaction":"VOMITING"},{"count":6,"reaction":"ERYTHEMA"},{"count":5,"reaction":"CONVULSION"},{"count":5,"reaction":"DYSPNOEA"},{"count":5,"reaction":"PRURITUS"},{"count":5,"reaction":"RASH"}],"crossReferences":{"chemblId":"CHEMBL1201529"},"_approvalHistory":[{"date":"20231109","type":"ORIG","sponsor":"JUBILANT","applicationNumber":"ANDA213516"},{"date":"20140912","type":"SUPPL","sponsor":"SUN PHARM INDS INC","applicationNumber":"NDA017858"},{"date":"19820630","type":"SUPPL","sponsor":"SUN PHARM INDS INC","applicationNumber":"NDA017858"},{"date":"20151204","type":"SUPPL","sponsor":"SUN PHARM INDS INC","applicationNumber":"NDA017858"},{"date":"19820127","type":"SUPPL","sponsor":"SUN PHARM INDS INC","applicationNumber":"NDA017858"},{"date":"20121214","type":"SUPPL","sponsor":"SUN PHARM INDS INC","applicationNumber":"NDA017858"},{"date":"20150922","type":"SUPPL","sponsor":"SUN PHARM INDS INC","applicationNumber":"NDA017858"},{"date":"20120813","type":"SUPPL","sponsor":"SUN PHARM INDS INC","applicationNumber":"NDA017858"},{"date":"19860402","type":"SUPPL","sponsor":"SUN PHARM INDS INC","applicationNumber":"NDA017858"},{"date":"19850802","type":"SUPPL","sponsor":"SUN PHARM INDS INC","applicationNumber":"NDA017858"},{"date":"19980804","type":"SUPPL","sponsor":"SUN PHARM INDS INC","applicationNumber":"NDA017858"},{"date":"19860912","type":"SUPPL","sponsor":"SUN PHARM INDS INC","applicationNumber":"NDA017858"},{"date":"19950825","type":"SUPPL","sponsor":"SUN PHARM INDS INC","applicationNumber":"NDA017858"},{"date":"19850226","type":"SUPPL","sponsor":"SUN PHARM INDS INC","applicationNumber":"NDA017858"},{"date":"19820111","type":"SUPPL","sponsor":"SUN PHARM INDS INC","applicationNumber":"NDA017858"},{"date":"20131204","type":"SUPPL","sponsor":"SUN PHARM INDS INC","applicationNumber":"NDA017858"},{"date":"20150928","type":"SUPPL","sponsor":"SUN PHARM INDS INC","applicationNumber":"NDA017858"},{"date":"19800511","type":"SUPPL","sponsor":"SUN PHARM INDS INC","applicationNumber":"NDA017858"},{"date":"19780417","type":"ORIG","sponsor":"SUN PHARM INDS INC","applicationNumber":"NDA017858"},{"date":"20150813","type":"SUPPL","sponsor":"SUN PHARM INDS INC","applicationNumber":"NDA017858"},{"date":"20110722","type":"SUPPL","sponsor":"SUN PHARM INDS INC","applicationNumber":"NDA017858"},{"date":"20160422","type":"SUPPL","sponsor":"SUN PHARM INDS INC","applicationNumber":"NDA017858"},{"date":"20020913","type":"SUPPL","sponsor":"SUN PHARM INDS INC","applicationNumber":"NDA017858"},{"date":"19850429","type":"SUPPL","sponsor":"SUN PHARM INDS INC","applicationNumber":"NDA017858"},{"date":"19890922","type":"SUPPL","sponsor":"SUN PHARM INDS INC","applicationNumber":"NDA017858"},{"date":"19840910","type":"SUPPL","sponsor":"SUN PHARM INDS INC","applicationNumber":"NDA017858"},{"date":"19811116","type":"SUPPL","sponsor":"SUN PHARM INDS INC","applicationNumber":"NDA017858"},{"date":"20191219","type":"SUPPL","sponsor":"SUN PHARM INDS INC","applicationNumber":"NDA017858"}],"publicationCount":1718,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["99mTc-SC","99mTc-SC Sulfur Colloid"],"phase":"marketed","status":"active","brandName":"Sulfur Colloid","genericName":"Sulfur Colloid","companyName":"University of California, San Diego","companyId":"university-of-california-san-diego","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":1},"validation":{"fieldsValidated":4,"lastValidatedAt":"2026-04-20T06:57:54.905112+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}